US 9234196
Compositions and methods for inhibiting expression of transthyretin
granted A61KA61K31/713A61K9/0019
Quick answer
US patent 9234196 (Compositions and methods for inhibiting expression of transthyretin) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 37
- CPC classes
- A61K, A61K31/713, A61K9/0019, A61P, A61P1/00